/PRNewswire -- Nov. 10/
WHAT Sanofi-aventis CEO Chris Viehbacher and Sanofi Pasteur President & CEO Wayne Pisano will discuss how the company is meeting the challenges of manufacturing A (H1N1) vaccine. David Greenberg, M.D., Senior Director, Scientific and Medical Affairs, Sanofi Pasteur, will provide new data from adult and pediatric clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine. WHY Sanofi Pasteur, the largest company in the world devoted entirely to vaccines -- and the only company producing an inactivated influenza vaccine at a manufacturing facility located in the United States -- has worked closely with the U.S. Department of Health and Human Services and other public health agencies to develop and produce a safe A (H1N1) vaccine that provides a robust immune response. Sanofi Pasteur's U.S. facility has been operating 24 hours a day, seven days a week to produce A (H1N1) vaccine. WHEN 2:30 p.m. ET Wednesday, November 11, 2009 HOW To participate in this Webcast briefing, click on the following link to register and for further login instructions: http://www.visualwebcaster.com/event.asp?id=63928 Please Note: Participants should be sure to run a system check when registering to confirm system compatibility. To perform this check, click the link below the registration form. CONTACT For additional information: Freeman Miller Burson-Marsteller on behalf of Sanofi Pasteur 212-614-4216 [email protected]
SOURCE Sanofi Pasteur
